Emergency approval for IntelligentMDx's H1N1 test
This article was originally published in Clinica
Executive Summary
An H1N1 test from IntelligentMDx (IMDx) has become the latest to be granted emergency use authorisation (EUA) from the US FDA for pandemic flu. The company claims the Influenza A H1N1 real-time RT-PCR assay is the first authorised for use on multiple instruments. This includes Applied Biosystems' 7500 Fast real-time PCR system and 7500 Fast Dx real-time PCR instrument. The test produces results in 90 minutes, Cambridge, Massachusetts-based IMDx says, and is intended for use in labs with high-complexity CLIA certification. The diagnostic will now be available for the duration of the emergency declaration, which is set to expire on April 26 2010.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.